tiprankstipranks
Pieris Pharmaceuticals (DE:PI6)
FRANKFURT:PI6

Pieris Pharmaceuticals (PI6) Stock Price & Analysis

0 Followers

PI6 Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range€0.12 - €0.86
Previous Close€0.14
Volume31.10K
Average Volume (3M)15.82K
Market Cap
€14.40M
Enterprise Value-€16.23M
Total Cash (Recent Filing)$44.81M
Total Debt (Recent Filing)$12.29M
Price to Earnings (P/E)N/A
Beta1.00
May 08, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding98,935,025
10 Day Avg. Volume0
30 Day Avg. Volume15,820
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.51
Price to Sales (P/S)2.41
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.33
Enterprise Value/Gross Profit-0.63
Enterprise Value/Ebitda-1.36
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

0.00%0.00%0.01%99.99%
0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors

PI6 FAQ

What was Pieris Pharmaceuticals’s price range in the past 12 months?
Pieris Pharmaceuticals lowest stock price was €0.12 and its highest was €0.86 in the past 12 months.
    What is Pieris Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Pieris Pharmaceuticals’s upcoming earnings report date?
    Pieris Pharmaceuticals’s upcoming earnings report date is May 08, 2024 which is in 13 days.
      How were Pieris Pharmaceuticals’s earnings last quarter?
      Pieris Pharmaceuticals released its earnings results on Mar 27, 2024. The company reported -€0.043 earnings per share for the quarter, beating the consensus estimate of -€0.113 by €0.07.
        Is Pieris Pharmaceuticals overvalued?
        According to Wall Street analysts Pieris Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Pieris Pharmaceuticals pay dividends?
          Pieris Pharmaceuticals does not currently pay dividends.
          What is Pieris Pharmaceuticals’s EPS estimate?
          Pieris Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Pieris Pharmaceuticals have?
          Currently, no data Available
          What happened to Pieris Pharmaceuticals’s price movement after its last earnings report?
          Pieris Pharmaceuticals reported an EPS of -€0.043 in its last earnings report, beating expectations of -€0.113. Following the earnings report the stock price went same 0%.
            Which hedge fund is a major shareholder of Pieris Pharmaceuticals?
            Among the largest hedge funds holding Pieris Pharmaceuticals’s share is Platinum Investment Management. It holds Pieris Pharmaceuticals’s shares valued at N/A.
              ---

              Pieris Pharmaceuticals Stock Smart Score

              Company Description

              Pieris Pharmaceuticals

              Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.
              ---

              PI6 Earnings Call

              Q1 2023
              0:00 / 0:00
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              Pieris Pharmaceuticals
              Adverum Biotechnologies
              Agios Pharma
              Novavax
              Crispr Therapeutics AG
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis